MENU

OUR CORE CAPABILITIES

Molekule delivers long-term consultative partnerships with insights, pricing and market access, franchise and brand partners across the global pharma matrix to develop and deliver insights against brand, franchise and corporate strategic imperatives.
We maintain a broad and growing, actively managed, global persistent human source network. We offer highly customized CI training programs and help educate internal customers and contributors on the value of CI.
Commercial and R&D Competitive
Intelligence Services
- Focused Launch Logistics Including Go-to-Market Strategy Assessments

- Strategic Pricing and Access, Contracting & Reimbursement Research
- Launch Prioritization & Segmentation Research

- Pipeline Optimization & Competitive Assessments
- Licensing & M&A Support

- Payer Assessments and Competitive Landscaping
Strategy & Competitive Scenario Planning
- Competitor Profiling and Monitoring

- Payer and Access Research

- Strategic workshops
- Competitive Simulations and CI Process Consulting & CI Training

- Franchise Strategy and FMEA (failure mode effects analysis)
- Biopharmaceutical Strategic Consulting Positioning

- Early warning programs and landscape monitoring
Generics & Biosimilars
- Congress and event coverage

- Pre-, Peri- and Post- LoE Assessments
- Regulatory Landscape Assessments Regarding Generics and Biosimilar Threats
- Generic/Biosimilar Landscape Monitoring – Proactive Research
Manufacturing & Supply Chain Logistics
- Manufacturing and Technology Assessments of Competitor Facilities, Equipment and Technologies
- Manufacturing and Supply Chain Logistics Deep-dives & Benchmarking
- Manufacturing & COGS Analyses

THERAPEUTIC AREAS OF EXPERTISE

Anti-Infectives
Cardiovascular
CNS
Dermatology
Endocrinology
Gastroenterology
Hematology
Immunology
Metabolic Diseases
Oncology
Ophthalmology
Orphan Diseases
Pain
Respiratory
Sexual Medicine
Urology
Vaccines
Women’s Health

Our knowledge & experience in market intelligence

Molekule’s robust experience in market intelligence spans numerous engagements in support of biopharmaceutical companies, brand teams, and biopharmaceutical executive leadership on a global scope and scale.
Molekule continues to evolve its global organic source network across key biopharmaceutical, medical device and life sciences players via continued and regular congress attendance and active project engagement.

Operating geographies & capabilties

Molekule’s Specific
U.S. Capabilities
Molekule Specific
European Capabilities
Molekule Specific
LATAM Capabilities
Molekule Specific
Asia-Pacific Capabilities
Molekule’s Specific U.S. Capabilities
Molekule is headquartered in Miami, FL and has strategically positioned offices in New York City and New Jersey.
Molekule consultants solely conduct ethical, elicitation-style competitive intelligence primary research - neither honorarium, nor compensation are rendered to respondents. All conversations are non-transactional.
The U.S.-market and U.S.-headquartered biopharma represent ~50% of Molekule’s total annual workload.
Molekule annually conducts more than 60 U.S.-based primary research projects and 15+ competitive simulations - the team also attends 50+ U.S. congresses across therapy areas and subject matters.
Our U.S.-team understands the nuances of U.S.-market pricing & market access, regulatory, go-to-market strategy, field force sizing and structure and generics & biosimilars - we are therefore, well-positioned to support.
Molekule’s Specific European Capabilities
Molekule established its European HQ in 2017 to specifically serve the European market.
Molekule has conducted 27 projects in the last 12 months in Europe covering EU5, Nordic countries, Eastern European countries, Switzerland, and others.
Molekule consultants are “fluent” in 17 languages and therefore can conduct most primary CI interviews in the native language of the person interviewed.
Molekule has in-house consultants on the ground in many of the major European countries.
Today, 40% of Molekule’s work is for European companies and/or focus is the European market.
Molekule Consulting's LATAM Engagement Experience
Molekule maintains a highly granularized and dialed-in perspective regarding the LATAM biopharmaceutical market - commercial/marketing, regulatory/technical, clinical/medical and manufacturing/supply chain logistics - in support of our client partners.
Understanding the regulatory, manufacturing and supply chain logistics, clinical and commercial dynamics of LATAM-based biosimilars players for three (3) key oncology biologic assets in key markets (Argentina, Brazil, Bolivia, Chile, Cuba, Mexico, Venezuela)
Targeted due diligence and threat assessment of Brazil-based local, regional and extra-regional (i.e.- MNC biopharmaceutical companies with a presence in Brazil) biopharmaceutical players and their intentions to establish distribution hubs/nodes in the Brazil market
Due diligence assessment: a Brazil-based Biotech, a Mexico Based Biotech, and a Russia-based Biotech as potential LATAM alliance partners and/or M&A targets
Elucidation of local-MNC partnerships among LATAM-based biopharmaceutical players and potential and/or realized MNC pharmacos
Competitive intelligence assessment of the LATAM generics and innovator small molecule pharmaceutical market in Argentina, Brazil, Cuba and Mexico
Regulatory assessment of ANVISA’s “risk tolerance appetite” for MNC biopharmaceutical companies’ regulatory dossiers and forecasting of the subsequent pricing & reimbursement of these assets, forward-looking
Targeted assessment: Fiocruz (Bio-Manguinhos) and its vaccines and biosimilars capabilities for the LATAM market
Our Deep and Significant Experience In Asia-Pacific (“A-P”) and Asean Markets
A Select View of Molekule’s A-P AND ASEAN FOCUSED Engagements
Determining the competitive threat of a China-based biopharmaceutical player with respect to its anti VEGF ophthalmology asset; a focused assessment of ex-China opportunity, strategic intent and tactical implementation
Focused assessment of a mid-sized Japan-based pharmaceutical player to determine ex-Japan strategic intentions with respect to a high potential developmental biosimilar asset
Targeted assessment of ASEAN local and regional diabetes players: how will diabetes competitors leverage a portfolio of both injectable and oral antidiabetic agents to drive an extra-regional Asia-Pacific strategy.
Deep dive assessment of emerging Asia-Pacific markets – Thailand, Malaysia, China, S. Korea, Vietnam and Cambodia – MNC biopharmas’ strategic intent, tactical implementation and overt mid-range strategic plans
Comprehensive assessment of emerging Korea-based biosimilars competitors: determining developmental portfolio strategies & priorities, partnerships & tie-ups and long-range commercialization plans
Understanding the emerging novel anti-viral market in key Tier II/Tier III ASEAN and Asia-Pacific markets
Comprehensive landscape monitoring of diosgenin and androstenedione manufacturing, distribution, wholesale, trade and resale in Asia-Pacific markets

Operating geographies & captabilties

Molekule’s Specific U.S. Capabilities
Molekule Specific European Capabilities
Molekule Specific LATAM Capabilities
Molekule Specific
Asia-Pacific Capabilities
Molekule’s Specific U.S. Capabilities
Molekule is headquartered in Miami, FL and has strategically positioned offices in New York City and New Jersey.
Molekule consultants solely conduct ethical, elicitation-style competitive intelligence primary research…neither honorarium, nor compensation are rendered to respondents. All conversations are non-transactional.
The U.S.-market and U.S-headquartered biopharma represent ~50% of Molekule’s total annual workload.
Molekule annually conducts more than 60 U.S.-based primary research projects and 15+ competitive simulations…. the team also attends 50+ U.S. congresses across therapy areas and subject matters.
Our U.S.-team understands the nuances of U.S.-market pricing & market access, regulatory, go-to-market strategy, field force sizing and structure and generics & biosimilars.. we are therefore, well-positioned to support.
Molekule’s Specific European Capabilities
Molekule established its European HQ in 2017 to specifically serve the European market.
Molekule has conducted 27 projects in the last 12 months in Europe covering EU5, Nordic countries, Eastern European countries, Switzerland, and others.
Molekule consultants are “fluent” in 17 languages and therefore can conduct most primary CI interviews in the native language of the person interviewed.
Molekule has in-house consultants on the ground in many of the major European countries.
Today, 40% of Molekule’s work is for European companies and/or focus is the European market.
Molekule's Consulting LATAM Engagement Experience
Molekule maintains a highly granularized and dialed-in perspective regarding the LATAM biopharmaceutical market - commercial/marketing, regulatory/technical, clinical/medical and manufacturing/supply chain logistics - in support of our client partners.
Understanding the regulatory, manufacturing and supply chain logistics, clinical and commercial dynamics of LATAM-based biosimilars players for three (3) key oncology biologic assets in key markets (Argentina, Brazil, Bolivia, Chile, Cuba, Mexico, Venezuela)
Targeted due diligence and threat assessment of Brazil-based local, regional and extra-regional (i.e.- MNC biopharmaceutical companies with a presence in Brazil) biopharmaceutical players and their intentions to establish distribution hubs/nodes in the Brazil market
Due diligence assessment: a Brazil-based Biotech, a Mexico Based Biotech, and a Russia-based Biotech as potential LATAM alliance partners and/or M&A targets
Elucidation of local-MNC partnerships among LATAM-based biopharmaceutical players and potential and/or realized MNC pharmacos
Competitive intelligence assessment of the LATAM generics and innovator small molecule pharmaceutical market in Argentina, Brazil, Cuba and Mexico
Regulatory assessment of ANVISA’s “risk tolerance appetite” for MNC biopharmaceutical companies’ regulatory dossiers and forecasting of the subsequent pricing & reimbursement of these assets, forward-looking
Targeted assessment: Fiocruz (Biomanguinhos) and its vaccines and biosimilars capabilities for the LATAM market
Our Deep and Significant Experience In Asia-Pacific (“A-P”) and Asean Markets
A Select View of Molekule’s A-P AND ASEAN FOCUSED Engagements
Determining the competitive threat of a China-based biopharmaceutical player with respect to its anti VEGF ophthalmology asset; a focused assessment of ex-China opportunity, strategic intent and tactical implementation
Focused assessment of a mid-sized Japan-based pharmaceutical player to determine ex-Japan strategic intentions with respect to a high potential developmental biosimilar asset
Targeted assessment of ASEAN local and regional diabetes players: how will diabetes competitors leverage a portfolio of both injectable and oral antidiabetic agents to drive an extra-regional Asia-Pacific strategy.
Deep dive assessment of emerging Asia-Pacific markets – Thailand, Malaysia, China, S. Korea, Vietnam and Cambodia – MNC biopharmas’ strategic intent, tactical implementation and overt mid-range strategic plans
Comprehensive assessment of emerging Korea-based biosimilars competitors: determining developmental portfolio strategies & priorities, partnerships & tie-ups and long-range commercialization plans
Understanding the emerging novel anti-viral market in key Tier II/Tier III ASEAN and Asia-Pacific markets
Comprehensive landscape monitoring of diosgenin and androstenedione manufacturing, distribution, wholesale, trade and resale in Asia-Pacific markets
cross
linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram